Back

Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin

European Heart Journal

18 November 2020
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY PREVENTIVE CARDIOLOGY Risk Factors and Prevention Pharmacology and Pharmacotherapy

Contributors

Naveed Sattar
Naveed Sattar

Author

University of Glasgow Glasgow , United Kingdom of Great Britain & Northern Ireland

Darren K McGuire
Darren K McGuire

Author

University of Texas Southwestern Medical Center Dallas , United States of America

You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
27 August 2023
thumbnail
Congress Presentation
Metformin reduces the risk of hospitalization for heart failure in type 2 diabetes patients: a retrospective cohort analysis
3 September 2019
thumbnail
Congress Presentation
Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis
27 August 2021
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
6 July 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources